Abstract: A method for treating a gluten-induced disease, such as celiac disease, in a subject in need thereof is provided. The method comprises administering to the subject at least one agent that activates aryl hydrocarbon receptor such as AhR agonists, bacterial probiotics with AhR agonist activity, and IL-22 agonists, polypeptides and nucleic acid.

Abstract: Novel proteins from Streptococcus pneumoniae are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.

Abstract: Novel proteins from Streptococcus pneumoniae are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.

Abstract: There are provided various novel antigens from Streptococcus pneumoniae, as well as homologues, derivatives and fragments thereof. The use of these in medicine is described, particularly in the treatment or prophylaxis of S. pneumoniae infections. The use of the antigens in diagnosis is also described.

Abstract: Novel proteins from Streptococcus pneumoniae are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.

Abstract: Novel protein antigens from Group B Streptococcus are described, together with nucleic acid sequences encoding them. Their use in vaccines and screening methods is also described.

Abstract: Novel proteins from Streptococcus pneumoniae are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.

Abstract: There are provided various novel antigens from Streptococcus pneumoniae, as well as homolgoues, derivatives and fragments thereof. The use of these in medicine is described, particularly in the treatment or prophylaxis of S. pneumoniae infections. The use of the antigens in diagnosis is also described.

Abstract: Biologically active polypeptides and/or antigens are delivered by administering to a subject a non-invasive or non-pathogenic bacterium which expresses one or more antigens or polypeptides. The non-invasive or non-pathogenic bacterium can be included in delivery systems or pharmaceutical formulations.

Abstract: Novel protein antigens from Group B Streptococcus are described, together with the nucleic acid sequences encoding them. The use of vaccines and screening methods is also described.

Abstract: The present invention relates to detoxified immunogenic derivatives of Clostridium perfringens &bgr;-toxin or an immunogenic fragment thereof that have as a characteristic that they carry a mutation in the &bgr;-toxin amino acid sequence, not found in the wild-type &bgr;-toxin amino acid sequence. The invention also relates to genes encoding such &bgr;-toxins, as well as to expression systems expressing such &bgr;-toxins. Moreover, the invention relates to bacterial expression systems expressing a native &bgr;-toxin. Finally, the invention relates to vaccines based upon detoxified immunogenic derivatives of Clostridium perfringens &bgr;-toxin, and methods for the preparation of such vaccines.

Abstract: Biologically active polypeptides and/or antigens are delivered by administering to a subject a non-invasive or non-pathogenic bacterium which expresses one or more antigens or polypeptides. The non-invasive or non-pathogenic bacterium can be included in delivery systems or pharmaceutical formulations.

Abstract: Novel protein antigens from Group B Streptococcus are described, together with nucleic acid sequences encoding them. Their use in vaccines and screening methods is also described.

Abstract: Novel proteins from Streptococcus pneumoniae are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.

Abstract: There are provided various novel antigens from Streptococcus pneumoniae, as well as homolgoues, derivatives and fragments thereof. The use of these in medicine is described, particularly in the treatment or prophylaxis of S. pneumoniae infections. The use of the antigens in diagnosis is also described.

Abstract: Methods of delivering biologically active polypeptides and/or antigens by administering to a subject a non-invasive or non-pathogenic bacterium which expresses the one or more antigens or polypeptides. Also, nucleic acids, delivery systems, pharmaceutical formulations comprising such delivery systems and methods of making same.

Abstract: Heterologous polypeptides are produced in lactococcus using a T7 or T7-like RNA polymerase gene under the control of an inducible promoter effective in a lactococcus host, and a promoter specific for said polymerase upstream of a coding sequence for the heterologous polypeptide. Thus, the promoter specific for the polymerase directs transcription of the coding sequence selectively as a result of expression of the polymerase. The heterologous polypeptide can be produced at high yield, and can be secreted. The polypeptide within the cell, being biologically active, can be delivered in the encapsulated form, e.g. as a medicament, vaccine or as an environmental pesticide.

Abstract: Methods for obtaining surface expression of a desired protein or polypeptide in Gram-positive host organisms are provided. In addition, vectors useful in such methods as well as Gram-positive host organisms transformed with such vectors are disclosed.